Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 study of BGB-45035

Trial Profile

Phase 2 study of BGB-45035

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BGB 45035 (Primary)
  • Indications Autoimmune disorders
  • Focus Proof of concept; Therapeutic Use

Most Recent Events

  • 07 May 2025 According to BeiGene media release, first patient enrollment and proof-of-concept data for tissue IRAK4 degradation are planned in 2H2025.
  • 03 Mar 2025 New trial record
  • 27 Feb 2025 According to BeiGene media release, Phase 2 study is planned in second half of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top